Furthermore, the overexpression of HER2 triggers the HER2-IL-6- signal transducer and activator of transcription 3 (STAT3) signaling cascade, which stimulates breast cancer stem cells to self-renew and develop resistance to anti-HER2 therapy.62 Here, IL6 is linked to breast carcinoma.